Biopsy needle market seen reaching $2.06 billion by 2030

The biopsy needle market is projected to grow from $1.52 billion in 2026 to $2.06 billion by 2030, according to a new industry report. Demand is being lifted by minimally invasive procedures, rising cancer cases, and wider use of image-guided and disposable biopsy tools.

Why it matters: - Biopsy needles are a core tool for diagnosing cancer, infections, and other abnormalities with less invasive tissue sampling. - The market’s projected growth signals sustained demand for faster, safer diagnostic procedures across hospitals, surgical centers, clinics, and labs. - The report points to expanding use of image-guided and vacuum-assisted biopsy technologies as a major shift in how tissue samples are collected.

What happened: - The Business Research Company published a biopsy needle market report covering 2026-2035. - The report estimates the market will rise from $1.41 billion in 2025 to $1.52 billion in 2026. - The report forecasts the market will reach $2.06 billion by 2030. - The report places the market on a 7.8% CAGR path from 2025 to 2026 and a 7.9% CAGR path through 2030. - North America held the largest market share in 2025. - Asia-Pacific is expected to grow the fastest over the forecast period.

The details: - Historical growth was supported by continued use of core needle biopsy techniques. - Limited access to vacuum-assisted biopsy systems also shaped recent demand. - Rising cancer incidence worldwide increased use of biopsy needles. - Better hospital and surgical center infrastructure supported market expansion. - Greater awareness of early diagnosis contributed to adoption. - Future growth is expected to come from image-guided biopsy systems and vacuum-assisted biopsy technologies. - Advanced disposable needle designs are also expected to support demand. - Growth in diagnostic clinics and pathology labs should add to market volume. - The report also points to higher research spending and use of artificial intelligence and digital tools to improve diagnostic accuracy. - Notable trends include wider use of image-guided biopsies, preference for disposable needles, more minimally invasive diagnostics, broader cancer screening programs, and tighter patient safety and sterilization protocols. - A biopsy needle is a medical instrument used to collect tissue samples for diagnostic analysis, often with imaging guidance. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. - The report’s downloadable sample is available here. - The full report is available here.

Between the lines: - The market outlook reflects a broader shift toward outpatient-style diagnostics that reduce pain, recovery time, and complication risk. - Rising adoption of minimally invasive procedures in other medical areas helps explain why biopsy tools are gaining traction. - The addition of AI and digital tools suggests diagnostic workflows are becoming more automated and data-driven. - The emphasis on disposable needles and sterilization protocols points to infection control and patient safety as purchasing priorities.

What's next: - The report expects biopsy needle demand to keep rising as cancer screening expands and imaging-based diagnosis becomes more common. - Regional growth is likely to remain strongest in Asia-Pacific as healthcare access and diagnostic capacity expand. - Market reporting from The Business Research Company now includes market attractiveness scoring, TAM analysis, company scoring matrices, forecasting dashboards, hotspots graphics, and updated trend analysis. - The company listed contact channels for report inquiries, including email at marketing@tbrc.info and phone numbers for the Americas, Asia, and Europe.

The bottom line: - Biopsy needles are moving from a steady diagnostic staple to a growth market tied to minimally invasive care, cancer detection, and imaging-led medicine.